Literature DB >> 23208805

[Genetic diagnostic testing in inherited retinal dystrophies].

S Kohl1, S Biskup.   

Abstract

Inherited retinal dystrophies are clinically and genetically highly heterogeneous. They can be divided according to the clinical phenotype and course of the disease, as well as the underlying mode of inheritance. Isolated retinal dystrophies (i.e., retinitis pigmentosa, Leber's congenital amaurosis, cone and cone-rod dystrophy, macular dystrophy, achromatopsia, congenital stationary nightblindness) and syndromal forms (i.e., Usher syndrome, Bardet-Biedl syndrome) can be differentiated. To date almost 180 genes and thousands of distinct mutations have been identified that are responsible for the different forms of these blinding illnesses. Until recently, there was no adequate diagnostic genetic testing available. With the development of the next generation sequencing technologies, a comprehensive genetic screening analysis for all known genes for inherited retinal dystrophies has been established at reasonable costs and in appropriate turn-around times. Depending on the primary clinical diagnosis and the presumed mode of inheritance, different diagnostic panels can be chosen for genetic testing. Statistics show that in 55-80 % of the cases the genetic defect of the inherited retinal dystrophy can be identified with this approach, depending on the initial clinical diagnosis. The aim of any genetic diagnostics is to define the genetic cause of a given illness within the affected patient and family and thereby i) confirm the clinical diagnosis, ii) provide targeted genetic testing in family members, iii) enable therapeutic intervention, iv) give a prognosis on disease course and progression and v) in the long run provide the basis for novel therapeutic approaches and personalised medicine. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2012        PMID: 23208805     DOI: 10.1055/s-0032-1327929

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  3 in total

1.  Genetic Testing of Inherited Retinal Disease in Australian Private Tertiary Ophthalmology Practice.

Authors:  Sena A Gocuk; Yuanzhang Jiao; Alexis Ceecee Britten-Jones; Nathan M Kerr; Lyndell Lim; Simon Skalicky; Richard Stawell; Lauren N Ayton; Heather G Mack
Journal:  Clin Ophthalmol       Date:  2022-04-13

2.  Identification of novel mutations by targeted exome sequencing and the genotype-phenotype assessment of patients with achromatopsia.

Authors:  Fen-Fen Li; Xiu-Feng Huang; Jie Chen; Xu-Dong Yu; Mei-Qin Zheng; Fan Lu; Zi-Bing Jin; De-Kang Gan
Journal:  J Transl Med       Date:  2015-10-22       Impact factor: 5.531

3.  Retinal Neuroprotective Effects of Flibanserin, an FDA-Approved Dual Serotonin Receptor Agonist-Antagonist.

Authors:  Aaron S Coyner; Renee C Ryals; Cristy A Ku; Cody M Fischer; Rachel C Patel; Shreya Datta; Paul Yang; Yuquan Wen; René Hen; Mark E Pennesi
Journal:  PLoS One       Date:  2016-07-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.